EAST WINDSOR, N.J.--(BUSINESS WIRE)--NexMed, Inc. (Nasdaq: NEXM), a developer of products based on the NexACT® drug delivery technology, today announced that four presentations on preclinical and clinical studies of NM100060, a topical onychomycosis (nail fungus) investigative drug product, will be made at the 67th Annual Meeting of the American Academy of Dermatology (AAD), in San Francisco, CA from March 6-10, 2009.
